The FDA issued an emergency use authorization (EUA) for convalescent plasma to treat coronavirus disease 2019 (COVID-19); limited transmission of COVID-19 was reported in reopened childcare centers; universal mask mandates could save lives.
Yesterday, the FDA issued an emergency use authorization for convalescent plasma as a treatment for coronavirus disease 2019 (COVID-19), according to STAT. Convalescent plasma, which is blood plasma derived from patients who have recovered from COVID-19, was touted by President Donald Trump’s press secretary as a major therapeutic breakthrough. However, the lack of confirmed clinical efficacy has drawn some skepticism among the scientific community, as current data suggest the therapy may not be effective for all patient populations.
According to a study conducted by the CDC that examined 666 reopened childcare centers this summer in Rhode Island, limited transmission of COVID-19 was reported among children and staff, which may inform decisions to reopen schools for in-person learning this fall. Reported by CIDRAP, CDC director Robert Redfield, MD, highlighted the significance of these findings, especially in areas with low cases of COVID-19 like Rhode Island. Redfield stressed that for schools to reopen safely, Americans must adhere to mask wearing, social distancing guidelines, and hand hygiene.
According to a projection by the University of Washington's Institute for Health Metrics and Evaluation (IHME), 70,000 lives can be saved by December if the United States issues universal mask mandates. Reported by The Hill, the study estimated that 134,000 Americans could die from COVID-19 by December if safety measures remain stagnant, and the projected death toll could rise if these measures are further laxed. Moreover, IHME predicts that if mask mandates remain the same, COVID-19 death rates would dip in September and increase later in the fall, totaling nearly 310,000 deaths by December 1, 2020. So far, the United States has reported 5.6 million cases of COVID-19 and more than 176,000 deaths.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen